All In Biotech

Investigational drug · Phase 2

BAY 3401016

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alport Syndrome.

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "BAY 3401016"

First trial start

2025

Nov 19, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "BAY 3401016", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Alport Syndrome

Approved drugs for the same conditions: Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "BAY 3401016" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Alport Syndrome

  • R3R01Phase 22 trials

    River 3 Renal Corp. · Diabetic Kidney Disease, Alport Syndrome, Focal Segmental Glomerulosclerosis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bayer.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.